Opendata, web and dolomites

OVOMATIC

IN-OVO AUTOMATION FOR CANCER DRUG DISCOVERY

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 OVOMATIC project word cloud

Explore the words cloud of the OVOMATIC project. It provides you a very rough idea of what is the project "OVOMATIC" about.

czech    expensive    prof    evaluation    france    university    toxicity    reproducible    off    cover    prototype    tests    grenoble    severe    spin    tested    ovomatic    model    assays    sensitive    small    time    inovotion    treatments    head    precede    united    play    arab    finalise    successful    industry    40k    clients    fast    africa    euros    2009    introduce    150    biotechs    2014    eliminate    efforts    months    initiate    share    dedicate    uk    currently    huge    automatable    strategies    mouse    perform    discovery    confirmed    molecule    stage    pathologies    embryos    efficacy    240    meet    diseases    performed    financial       pharmaceutical    landscape    usa    tool    proprietary    south    molecules    anti    demand    commercial    cancer    japan    drugs    mainly    drug    ovo    big    emirates    vivo    republic    always    fewer    worldwide    robot    consuming    academics    chick    save    orphan    revolutionize    automated    productivity    obstacle    solving    societal    billion    market    pharma    founded    viallet    insufficient    issue    automating   

Project "OVOMATIC" data sheet

The following table provides information about the project.

Coordinator
INOVOTION 

Organization address
address: BIOPOLIS 5 AVE DU GRAND SABLON
city: LA TRONCHE
postcode: 38700
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website http://www.inovotion.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.1.4. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology)
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-01-01   to  2017-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    INOVOTION FR (LA TRONCHE) coordinator 50˙000.00

Map

 Project objective

Currently, the in vivo step in the drug discovery process is always performed using the mouse model. This step is expensive and time-consuming, with an average cost of 40k€ per molecule tested and an average duration of 6-9 months. It represents a huge obstacle for the pharmaceutical industry, leading to fewer new drugs brought to market each year, and insufficient treatments for severe pathologies such as cancer or orphan diseases. INOVOTION can play a major role in solving this huge societal issue: we have the technology to revolutionize drug discovery by automating in vivo drug evaluation for efficacy and toxicity. INOVOTION is a spin-off of the University of Grenoble, founded in 2014 by Prof. Viallet. Our researchers have been working since 2009 on a new proprietary technology to perform “in ovo” assays that precede mouse testing, using chick embryos. Our tests allow researchers to eliminate low-value molecules at an early stage in the process, and to dedicate mouse testing for high-potential molecules only. Furthermore, our technology is reliable, reproducible, highly sensitive, fast and automatable. The successful 150 studies we performed for big pharma, small biotechs and academics (in the USA, France, UK, Japan, South Africa, Czech Republic and the United Arab Emirates) have confirmed the market demand for our technology. The worldwide market for in vivo testing is about 30 billion euros per year, mainly for cancer research, and INOVOTION has the technology to meet the market's needs. For each 1% in market share we cover, we could save the pharmaceutical industry up to 240 M€. The OVOMATIC project aims to initiate an automated “in ovo” process including developing a robot tool head prototype, and finalise the commercial and financial strategies of our approach. The long-range impact of the OVOMATIC project is to introduce this new tool into the pharmaceutical landscape, greatly increasing the productivity of our clients' anti-cancer drug discovery efforts.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "OVOMATIC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "OVOMATIC" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.4.;H2020-EU.2.3.1.)

FlexiBiome (2018)

Next Generation Microbiome Platform

Read More  

SEQURE (2018)

Targeted complete next-generation sequencing for companion diagnostics and personalized treatment of cancer

Read More  

N-IF (2017)

The N-IF mouse – a new and unique fibrosis model for preclinical efficacy studies

Read More